

## FORM 7

### MONTHLY PROGRESS REPORT

Name of CSE Issuer: SPT Sulphur Polymer Technologies Inc. (the "Issuer").

Trading Symbol: SEE

Number of Outstanding Listed Securities: 19,133,334

Date: Month of October 2015

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Exchange Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**Subsequent to October 31, 2015, the Canadian Securities Exchange ("CSE") granted conditional approval for the Issuer to acquire a 90% interest in LeenLife Pharma S.A. and resume trading. Pursuant to the acquisition of LeenLife Pharma S.A., the Company was required to file a comprehensive disclosure document as a Fundamental Change according to the CSE's Policy Number 8 with a corresponding trading halt on July 8, 2015. The comprehensive Form 2A filing was posted to the CSE website on October 30, 2015. In due course the Company will change its name to "LeenLife Pharma International Inc." under the Business Corporations Act (British Columbia).**

The Company entered into a Share Purchase Agreement dated July 7, 2015 to acquire a 90% interest in LeenLife Pharma S.A. (a Polish private company) (hereinafter referred to as “LeenLife Poland”), which has developed a process to isolate Omega 3 fatty acids from flax seeds. LeenLife Poland is currently engaged in PCT (Patent Cooperation Treaty) proceedings pertaining to granting patents to the following invention: “Health-giving foodstuff containing ethyl esters of fatty acids, namely of linen oil (flax seed oil), and method for obtaining the same”. The application for granting patent protection pertains to countries of the European Union (“EU”), the Russian Federation, Ukraine, Republic of Belarus, People’s Republic of China, Republic of Korea, Japan, Commonwealth of Australia, New Zealand, Republic of South Africa, State of Israel, Federative Republic of Brazil, United States of America and Canada. LeenLife was established in 2013.

The purchase price is comprised of 12,232,788 shares of the Company at a deemed issuance price of \$0.1875 per share for an aggregate value of \$2,293,648 and \$563,0444 in cash consideration due by January 31, 2016 to reimburse the vendors for tax resulting from their disposition of their shares of LeenLife Poland. The post-transaction capital of the Company is 31,366,121. LeenLife Poland shareholders will hold, in the aggregate, 39% of the post-transaction capital of the Company. There is no change of control resulting from this transaction. Securities issued in this transaction will be subject to applicable regulatory escrow requirements. A finder’s fee not exceeding 3% of the equity portion of the transaction will be paid after completion in connection with this transaction to an arm’s length party for sourcing the acquisition.

2. Provide a general overview and discussion of the activities of management.

**The Issuer entered into a Share Purchase Agreement dated July 7, 2015 to acquire a 90% interest in a Polish private company, LeenLife Pharma S.A. (“LeenLife Poland”), which has developed a process to isolate Omega 3 fatty acids from flax seeds. LeenLife Poland is currently engaged in PCT (Patent Cooperation Treaty) proceedings pertaining to granting patents to the following invention: “Health-giving foodstuff containing ethyl esters of fatty acids, namely of linen oil (flax seed oil), and method for obtaining the same”. The application for granting patent protection pertains to countries of the European Union, the Russian Federation, Ukraine, Republic of Belarus, People’s Republic of China, Republic of Korea, Japan, Commonwealth of Australia, New Zealand, Republic of South Africa, State of Israel, Federative Republic of Brazil, United States of America and Canada. LeenLife Poland was established in 2013.**

**The purchase price is comprised of 12,232,788 shares of the Issuer at a deemed issuance price of \$0.1875 per share, for an aggregate value of \$2,293,648 and \$563,044 in cash consideration due by January 31, 2016 to reimburse the vendors for tax resulting from their disposition of their shares of LeenLife Poland. The post-transaction capital of the Issuer will be 31,366,121.**

**LeenLife Poland shareholders will hold, in the aggregate, 39% of the post-transaction capital of the Issuer. There is no change of control resulting from this transaction. Securities issued in this transaction will be subject to applicable regulatory escrow requirements. A finder’s fee not exceeding 3% of the equity portion of the transaction will be paid after completion in connection with this transaction to an arm’s length party for sourcing the acquisition.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**Not applicable**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**Not applicable**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**Not applicable**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**Not applicable**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**Not applicable**

8. Describe the acquisition of new customers or loss of customers.

**Not applicable**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**Not applicable**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**Not applicable**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**Not applicable**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**Not applicable**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**Not applicable**

14. Provide details of any securities issued and options or warrants granted.

**Not applicable**

15. Provide details of any loans to or by Related Persons.

**Not applicable**

16. Provide details of any changes in directors, officers or committee members.

**Not applicable**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The trends and risks which are likely to impact the Issuer are detailed in Item 17 Risk Factors of the Issuer's Form 2A - Listing Statement dated December 8, 2014.**

#### **Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated November 5, 2015.

**Stan Lis**  
Name of Director or Senior Officer

*/s/ Stan Lis*  
Signature

**President and CEO**  
Official Capacity

<b>Issuer Details</b> <i>Name of Issuer</i> <b>SPT Sulphur Polymer Technologies Inc.</b>	<i>For Month End</i> <b>October 2015</b>	<i>Date of Report</i> <i>YY/MM/DD</i> <b>15/11/05</b>
<i>Issuer Address</i> <b>Suite 380 – 580 Hornby Street</b>		
<i>City/Province/Postal Code</i> <b>Vancouver, BC, V6C 3B6</b>	<i>Issuer Fax No.</i> <b>(604) 764-0518</b>	<i>Issuer Telephone No.</i> <b>(604) 764-0518</b>
<i>Contact Name</i> <b>Stan Lis</b>	<i>Contact Position</i> <b>President and CEO</b>	<i>Contact Telephone No.</i> <b>(604) 764-0518</b>
<i>Contact Email Address</i> <a href="mailto:stanlis1976@gmail.com">stanlis1976@gmail.com</a>	<i>Web Site Address</i>	